A randomized, observer-blinded, active-controlled Phase 2 trial evaluating of safety and tolerability of different doses and formulations NanoFlu vaccine for Influenza-virus-infections
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs NanoFlu vaccine-Novavax (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Novavax
- 25 Sep 2018 According to a Novavax media release, the first participants has been enrolled in the trial.
- 25 Sep 2018 Status changed from planning to recruiting, according to a Novavax media release.
- 09 May 2018 According to a Novavax media release, top-line data from this study is expected in the first quarter of 2019.